309 related articles for article (PubMed ID: 19528520)
1. The risks and costs of multiple-generic substitution of topiramate.
Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
[TBL] [Abstract][Full Text] [Related]
2. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.
Paradis PE; Latrémouille-Viau D; Moore Y; Mishagina N; Lafeuille MH; Lefebvre P; Gaudig M; Duh MS
Curr Med Res Opin; 2009 Jul; 25(7):1793-805. PubMed ID: 19505202
[TBL] [Abstract][Full Text] [Related]
3. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
5. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
6. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
[TBL] [Abstract][Full Text] [Related]
7. Economic burden associated with the use of generic antiepileptic drugs in the United States.
Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
[TBL] [Abstract][Full Text] [Related]
8. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
[TBL] [Abstract][Full Text] [Related]
9. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization.
Halkin H; Dushenat M; Silverman B; Shalev V; Loebstein R; Lomnicky Y; Friedman N
Ann Pharmacother; 2007 Jan; 41(1):29-34. PubMed ID: 17190847
[TBL] [Abstract][Full Text] [Related]
10. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E
Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014
[TBL] [Abstract][Full Text] [Related]
11. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
12. The risks and costs of multiple-generic substitution of topiramate.
Sethi NK; Torgovnick J; Sethi PK; Arsura E; Emmanuel Paradis P; Duh MS; Durkin MB; Wan GJ
Neurology; 2010 Feb; 74(8):701-2; author reply 701-2. PubMed ID: 20177127
[No Abstract] [Full Text] [Related]
13. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
Hansen RA; Qian J; Berg R; Linneman J; Seoane-Vazquez E; Dutcher SK; Raofi S; Page CD; Peissig P
Pharmacotherapy; 2017 Apr; 37(4):429-437. PubMed ID: 28152215
[TBL] [Abstract][Full Text] [Related]
14. Generic antiepileptic drugs and associated medical resource utilization in the United States.
Labiner DM; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Helmers SL
Neurology; 2010 May; 74(20):1566-74. PubMed ID: 20393142
[TBL] [Abstract][Full Text] [Related]
15. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
Rascati KL; Richards KM; Johnsrud MT; Mann TA
Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
17. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
[TBL] [Abstract][Full Text] [Related]
18. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
LeLorier J; Duh MS; Paradis PE; Latrémouille-Viau D; Lefebvre P; Manjunath R; Sheehy O
Curr Med Res Opin; 2008 Apr; 24(4):1069-81. PubMed ID: 18315941
[TBL] [Abstract][Full Text] [Related]
20. Generic substitution of antiepileptic drugs.
Sander JW; Ryvlin P; Stefan H; Booth DR; Bauer J
Expert Rev Neurother; 2010 Dec; 10(12):1887-98. PubMed ID: 21091318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
